Vivani Medical Inc
VANI1.390USD
+0.010+0.72%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
85.50MMarket Cap
LossP/E TTM
More Details of Vivani Medical Inc Company
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Vivani Medical Inc Info
Ticker SymbolVANI
Company nameVivani Medical Inc
IPO dateDec 05, 2014
CEOMendelsohn (Adam)
Number of employees42
Security typeOrdinary Share
Fiscal year-endDec 05
Address1350 S. Loop Road
CityALAMEDA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94502
Phone14155068462
Websitehttps://vivani.com/
Ticker SymbolVANI
IPO dateDec 05, 2014
CEOMendelsohn (Adam)
Company Executives of Vivani Medical Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jami Taylor
Mr. Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Dr. Dean Baker, Ph.D.
Dr. Dean Baker, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregg G. Williams
Mr. Gregg G. Williams
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Director
Independent Director
--
--
Ms. Alexandra Larson
Ms. Alexandra Larson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jami Taylor
Mr. Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Revenue Breakdown
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
2.20M
0.00%
Italy
642.04K
0.00%
China
337.90K
0.00%
France
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
7.67%
Mendelsohn (Adam)
5.15%
The Vanguard Group, Inc.
1.84%
Mendelsohn (Aaron)
1.49%
Other
52.98%
Shareholders
Shareholders
Proportion
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
7.67%
Mendelsohn (Adam)
5.15%
The Vanguard Group, Inc.
1.84%
Mendelsohn (Aaron)
1.49%
Other
52.98%
Shareholder Types
Shareholders
Proportion
Individual Investor
45.62%
Investment Advisor
4.32%
Investment Advisor/Hedge Fund
0.94%
Hedge Fund
0.09%
Venture Capital
0.02%
Other
49.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
58
3.96M
6.69%
-1.39M
2025Q2
69
33.60M
56.71%
-571.94K
2025Q1
72
33.70M
56.88%
-726.81K
2024Q4
67
33.96M
57.33%
+2.68M
2024Q3
70
30.79M
54.55%
-493.25K
2024Q2
72
30.73M
54.46%
-999.37K
2024Q1
71
31.19M
60.37%
+7.51M
2023Q4
76
28.47M
55.90%
+4.85M
2023Q3
88
28.13M
55.24%
+3.68M
2023Q2
94
27.99M
55.13%
+4.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Williams (Gregg)
18.29M
30.87%
+105.15K
+0.58%
Apr 22, 2025
Bolck (Joachim Eberhard)
5.60M
9.45%
--
--
Mar 31, 2025
Mendelsohn (Adam)
3.75M
6.34%
+58.33K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
1.43M
2.42%
+465.19K
+48.09%
Jun 30, 2025
Mendelsohn (Aaron)
1.09M
1.83%
--
--
Mar 31, 2025
Tanager Wealth Management LLP
1.02M
1.72%
-202.65K
-16.56%
Jun 30, 2025
Geode Capital Management, L.L.C.
353.90K
0.6%
-6.63K
-1.84%
Jun 30, 2025
Commonwealth Financial Network
330.53K
0.56%
--
--
Jun 30, 2025
Baker (Wilford Dean)
197.48K
0.33%
--
--
Mar 31, 2025
Monetary Management Group, Inc.
193.98K
0.33%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
Date
Type
Ratio
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
Aug 18, 2022
Merger
3→1
FAQs
Who are the top five shareholders of Vivani Medical Inc?
The top five shareholders of Vivani Medical Inc are:
Williams (Gregg) holds 18.29M shares, accounting for 30.87% of the total shares.
Bolck (Joachim Eberhard) holds 5.60M shares, accounting for 9.45% of the total shares.
Mendelsohn (Adam) holds 3.75M shares, accounting for 6.34% of the total shares.
The Vanguard Group, Inc. holds 1.43M shares, accounting for 2.42% of the total shares.
Mendelsohn (Aaron) holds 1.09M shares, accounting for 1.83% of the total shares.
Williams (Gregg) holds 18.29M shares, accounting for 30.87% of the total shares.
Bolck (Joachim Eberhard) holds 5.60M shares, accounting for 9.45% of the total shares.
Mendelsohn (Adam) holds 3.75M shares, accounting for 6.34% of the total shares.
The Vanguard Group, Inc. holds 1.43M shares, accounting for 2.42% of the total shares.
Mendelsohn (Aaron) holds 1.09M shares, accounting for 1.83% of the total shares.
What are the top three shareholder types of Vivani Medical Inc?
The top three shareholder types of Vivani Medical Inc are:
Williams (Gregg)
Bolck (Joachim Eberhard)
Mendelsohn (Adam)
Williams (Gregg)
Bolck (Joachim Eberhard)
Mendelsohn (Adam)
How many institutions hold shares of Vivani Medical Inc (VANI)?
As of 2025Q3, 58 institutions hold shares of Vivani Medical Inc, with a combined market value of approximately 3.96M, accounting for 6.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -50.03%.
What is the biggest source of revenue for Vivani Medical Inc?
In FY2019, the -- business generated the highest revenue for Vivani Medical Inc, amounting to -- and accounting for --% of total revenue.
